Pages that link to "Q39730118"
Jump to navigation
Jump to search
The following pages link to Identification of hypermethylated genes associated with cisplatin resistance in human cancers (Q39730118):
Displaying 50 items.
- MAGEB2 is activated by promoter demethylation in head and neck squamous cell carcinoma (Q21134039) (← links)
- Cancer drug resistance: redox resetting renders a way (Q26750753) (← links)
- Global analysis of DNA methylation by Methyl-Capture sequencing reveals epigenetic control of cisplatin resistance in ovarian cancer cell (Q28478564) (← links)
- Decitabine rescues cisplatin resistance in head and neck squamous cell carcinoma (Q28544907) (← links)
- Incorporating network structure in integrative analysis of cancer prognosis data. (Q30577859) (← links)
- DNA methyltransferase 3a and mitogen-activated protein kinase signaling regulate the expression of fibroblast growth factor-inducible 14 (Fn14) during denervation-induced skeletal muscle atrophy (Q33931130) (← links)
- S100P expression is a novel prognostic factor in hepatocellular carcinoma and predicts survival in patients with high tumor stage or early recurrent tumors (Q34778723) (← links)
- Association of promoter methylation of VGF and PGP9.5 with ovarian cancer progression. (Q35004607) (← links)
- NID2 and HOXA9 promoter hypermethylation as biomarkers for prevention and early detection in oral cavity squamous cell carcinoma tissues and saliva. (Q35091263) (← links)
- The combination of thioxodihydroquinazolinones and platinum drugs reverses platinum resistance in tumor cells by inducing mitochondrial apoptosis independent of Bax and Bak (Q35541834) (← links)
- Arsenic Toxicology: Translating between Experimental Models and Human Pathology (Q35591935) (← links)
- Contributions of the Epidermal Growth Factor Receptor to Acquisition of Platinum Resistance in Ovarian Cancer Cells (Q35767493) (← links)
- Downregulation of insulin-like growth factor-binding protein 7 in cisplatin-resistant non-small cell lung cancer (Q35911664) (← links)
- Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance (Q35925441) (← links)
- High expression of S100P is associated with unfavorable prognosis and tumor progression in patients with epithelial ovarian cancer (Q36057106) (← links)
- Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer (Q36067023) (← links)
- Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes (Q36105474) (← links)
- Prognostic and predictive significance of long interspersed nucleotide element-1 methylation in advanced-stage colorectal cancer (Q36220792) (← links)
- Phospho-ΔNp63α/SREBF1 protein interactions: bridging cell metabolism and cisplatin chemoresistance (Q36392145) (← links)
- Salivary biomarker development using genomic, proteomic and metabolomic approaches (Q36632967) (← links)
- G0S2 Suppresses Oncogenic Transformation by Repressing a MYC-Regulated Transcriptional Program (Q36642613) (← links)
- Epigenetic regulation of cyclooxygenase-2 by methylation of c8orf4 in pulmonary fibrosis (Q36661876) (← links)
- Repression of exogenous gene expression by the retinoic acid target gene G0S2. (Q36866235) (← links)
- ERα propelled aberrant global DNA hypermethylation by activating the DNMT1 gene to enhance anticancer drug resistance in human breast cancer cells (Q37190494) (← links)
- Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors (Q37493954) (← links)
- A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. (Q37711644) (← links)
- Epigenomics and interindividual differences in drug response (Q38055065) (← links)
- Epigenetic alterations in osteosarcoma: promising targets (Q38185555) (← links)
- DNA methylation as an early diagnostic marker of cancer (Review). (Q38205768) (← links)
- Poised epigenetic states and acquired drug resistance in cancer (Q38254072) (← links)
- The emerging landscape of salivary diagnostics. (Q38667953) (← links)
- Inhibiting CD146 by its Monoclonal Antibody AA98 Improves Radiosensitivity of Cervical Cancer Cells. (Q38744883) (← links)
- Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancer (Q39008172) (← links)
- Differential effects of 1,25-dihydroxyvitamin D₃ on oral squamous cell carcinomas in vitro (Q39011592) (← links)
- Role of 14-3-3σ in resistance to cisplatin in non-small cell lung cancer cells (Q39206879) (← links)
- Long-term cisplatin exposure promotes methylation of the OCT1 gene in human esophageal cancer cells (Q39262271) (← links)
- IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer. (Q39356827) (← links)
- Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling (Q39411453) (← links)
- Characterization of regulatory sequences in alternative promoters of hypermethylated genes associated with tumor resistance to cisplatin (Q41866851) (← links)
- Folic acid supplementation increases survival and modulates high risk HPV-induced phenotypes in oral squamous cell carcinoma cells and correlates with p53 mRNA transcriptional down-regulation (Q41900960) (← links)
- G0S2 represses PI3K/mTOR signaling and increases sensitivity to PI3K/mTOR pathway inhibitors in breast cancer (Q42515055) (← links)
- Prospective nested case-control study of feature genes related to leukemic evolution of myelodysplastic syndrome (Q45332140) (← links)
- Epigenetic modification of α-N-acetylgalactosaminidase enhances cisplatin resistance in ovarian cancer (Q47126401) (← links)
- Silencing of G0/G1 switch gene 2 in cutaneous squamous cell carcinoma. (Q47600127) (← links)
- Differences in cisplatin distribution in sensitive and resistant ovarian cancer cells: a TEM/NanoSIMS study. (Q47672975) (← links)
- 3-Oxoacid CoA transferase 1 as a therapeutic target gene for cisplatin-resistant ovarian cancer (Q49777403) (← links)
- SPIRE - combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial. (Q52609425) (← links)
- [The epigenome. Target for innovative therapies in head and neck carcinoma]. (Q53473691) (← links)
- Rewiring of cisplatin-resistant bladder cancer cells through epigenetic regulation of genes involved in amino acid metabolism (Q58788944) (← links)
- DNA hypermethylation biomarkers to predict response to cisplatin treatment, radiotherapy or chemoradiation: the present state of art (Q84632174) (← links)